Dr. Lynn Bedford, of the University of Nottingham will also take a closer look at the reasons for the formation of Lewy bodies — a build-up of proteins within nerve cells — in the brains of people with Parkinson’s.
This study is aimed at providing a platform for the development of drugs to stop nerve cell death.
Dr Kieran Breen, Director of Research and Development for the Parkinson’s Disease Society, said: “Researchers are the people who make the discoveries and forge the links between different research areas so clearly investing in people is key to furthering our understanding of Parkinson’s.
Parkinson’s is a progressive neurological condition caused by the death of nerve cells in the brain that produce the chemical dopamine, which is responsible for movement. The condition affects movements such as walking, talking, and writing. Its three main symptoms are tremor, muscular rigidity, and slowness of movement. Parkinson’s is a very individual condition and the rate and nature of progression varies from person to person.
Dr Bedford said: “This novel model of Parkinson’s will be crucial in helping to uncover and study why nerve cells die in the region of the brain affected in Parkinson’s disease.
“At Nottingham we have an excellent team who are committed to understanding this model. I look forward to driving this interesting new avenue of research and interacting with individuals, both researchers and clinicians, in the field of Parkinson’s.”
Source: University of Nottingham
Related News Articles
- Treadmill Exercise for Parkinson’s
- Neupro Approved by FDA for Parkinson’s
- New Method to Predict Parkinson’s and ALS
- Multiple Origins for Adult Anxiety
- Genetic Link to Happiness
- Roots and Wings
- Learning About the Results of Research
- Checklist of Questions for Clinical Trial Participants
- How Will Treatment in a Clinical Research Study Differ from Treatment Your Own Doctor Provides?
- Involvement of Family Members and Others
